Graft Vs Host Disease, Leukemia, B-cell, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Solid Tumor
Conditions
Brief summary
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Detailed description
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region. Subjects enrolled in this treatment protocol will receive oral continuous dosing with ibrutinib at the same dose and schedule they were receiving at the end of the respective parent study. Treatment may be continued as long as the subjects continue to derive benefit from treatment with ibrutinib until such time that ibrutinib becomes commercially available for the indication of the parent study. Clinical evaluations (including safety assessments) will be performed per local standard of care for each disease that was studied in the parent protocol. At each visit, all ongoing and new onset non-serious AEs leading to dose reduction or discontinuation, serious adverse events (SAEs), adverse events of special interest (AESI), pregnancy events, other malignancies, and special reporting situations will be recorded.
Interventions
DRUGIbrutinib
Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
Sponsors
Janssen Biotech, Inc., including Johnson & Johnson
Pharmacyclics Switzerland GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject must have participated in an eligible ibrutinib clinical trial, may derive clinical benefit from continued treatment or restart of treatment with ibrutinib in the opinion of the treating physician and does not have access to commercial ibrutinib within their region and/or the drug is not reasonably accessible to the patient within the respective region. * Ongoing continuous treatment with ibrutinib. * Subject must have completed all assessments in their parent protocol and want to continue treatment with ibrutinib. * Subject or their legally authorized representative must voluntarily sign and date an informed consent approved by an independent ethics committee (IEC)/institutional review board (IRB) to the long term treatment extension protocol and not withdrawn consent from the parent study. * Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control and a barrier method during the period of therapy and for 90 days after the last dose of drug.
Exclusion criteria
* Meeting any requirement in the parent protocol to permanently discontinue ibrutinib treatment. * Any condition or situation which, in the opinion of the treating physician, may interfere significantly with a subject's participation in the protocol. * Female subjects who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this protocol or within 90 days of last dose of drug treatment. Male subjects who plan to father a child while enrolled in this protocol or within 90 days after the last dose of drug treatment. * Unwilling or unable to participate in all required evaluations and procedures. * Unable to understand the purpose and risks of the protocol and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterize the drug safety profile by collecting long-term safety data for ibrutinib. | Up to 3 years and will be re-evaluated on an ongoing basis. | Number of participants with treatment emergent serious adverse events and adverse events of special interest as assessed by CTCAE v4.0. |
Countries
Australia, Canada, Czechia, France, Hungary, Italy, New Zealand, Poland, Russia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Outcome results
None listed